Journal
CARCINOGENESIS
Volume 43, Issue 1, Pages 12-20Publisher
OXFORD UNIV PRESS
DOI: 10.1093/carcin/bgab111
Keywords
-
Categories
Funding
- National Center for Advancing Translational Sciences [UL1 TR002243]
- National Cancer Institute [K99/R00CA230205, R50CA211206, R01CA235553]
- VanderbiltIngram Cancer Center [P30CA068485]
Ask authors/readers for more resources
A genetic variant, rs34331122, in the 22q11.21 locus was found to be associated with breast cancer risk and also regulated TBX1 gene expression. Higher expression of TBX1 was observed in breast cancer tumors and was associated with worse outcomes in patients. Knock-down of TBX1 inhibited breast cancer cell proliferation, migration, and invasion, and induced cell cycle arrest in the G1 phase.
We have previously identified a genetic variant, rs34331122 in the 22q11.21 locus, as being associated with breast cancer risk in a genome-wide association study. This novel variant is located in the intronic region of the T-box transcription factor 1 (TBX1) gene. Cis-expression quantitative trait loci analysis showed that expression of TBX1 was regulated by the rs34331122 variant. In the current study, we investigated biological functions and potential molecular mechanisms of TBX1 in breast cancer. We found that TBX1 expression was significantly higher in breast cancer tumor tissues than adjacent normal breast tissues and increased with tumor stage (P < 0.05). We further knocked-down TBX1 gene expression in three breast cancer cell lines, MDA-MB-231, MCF-7 and T47D, using small interfering RNAs and examined consequential changes on cell oncogenicity and gene expression. TBX1 knock-down significantly inhibited breast cancer cell proliferation, colony formation, migration and invasion. RNA sequencing and flow cytometry analysis revealed that TBX1 knock-down in breast cancer cells induced cell cycle arrest in the G1 phase through disrupting expression of genes involved in the cell cycle pathway. Furthermore, survival analysis using the online Kaplan-Meier Plotter suggested that higher TBX1 expression was associated with worse outcomes in breast cancer patients, especially for estrogen receptor-positive breast cancer, with HRs (95% Cls) for overall survival (OS) and distant metastasis free survival (DMFS) of 1.5 (1.05-2.15) and 1.55 (1.10-2.18), respectively. In conclusion, our results suggest that the TBX1 gene may act as a putative oncogene of breast cancer through regulating expressions of cell cycle-related genes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available